Type of antibody:
Primary antibodies, Recombinant antibodies
recombinant human IgG1
Alternative names:
IPD1, IRAK-4, NY-REN-64, REN64, Q69FE3

Extended validation for IRAK4 Antibody, anti-human, REAfinity™


Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA462
Cells were incubated with an excess of purified unconjugated IRAK4 (REA462) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Specifications for IRAK4 Antibody, anti-human, REAfinity™


Clone REA462 recognizes the human interleukin-1 receptor-associated kinase 4 (IRAK4) antigen, regardless of phosphorylation status. IRAK4 is a serine/threonine-protein kinase, which is also known as renal carcinoma antigen NY-REN-64. Interleukin-1 receptor-associated kinases (IRAKs) are key components in the signal transduction pathways utilized by interleukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R), and toll-like receptors (TLRs). Out of four members in the mammalian IRAK family, IRAK4 is considered to be the “master IRAK”, the only family member indispensable for IL-1R/TLR signaling. In MyD88-dependent TIR signaling, IRAK4 is the initial receptor-proximal protein kinase that is recruited and activated upon ligation of receptors, and it interacts with multiple, key downstream signaling molecules. Targeted deletion of IRAK4 in mice reveals severe defects in cytokine responses and downstream signaling pathways induced by IL-1R and TLRs. Cells derived from human patients, who are deficient in IRAK4 due to gene deletion/mutations, clearly exhibit impaired responses to IL-1, IL-18, or exogenous MyD88-dependent TLR ligands. Together with its broad impact on TLR and IL-1R signaling, IRAK4 may be a key target for therapeutic intervention in various inflammatory disorders.
Additional information: Clone REA462 displays negligible binding to Fc receptors.

Alternative names

IPD1, IRAK-4, NY-REN-64, REN64, Q69FE3

Detailed product information

Technical specifications

Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (I), human IgG1
Hosthuman cell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Alternative names of antigenIPD1, IRAK-4, NY-REN-64, REN64, Q69FE3
Molecular mass of antigen [kDa]52
Distribution of antigengranulocytes, monocytes, macrophages, eosinophils, neutrophils
Entrez Gene ID51135
RRIDAB_2733871, AB_2752058, AB_2752045, AB_2733870

Resources for IRAK4 Antibody, anti-human, REAfinity™


Please follow this
to search for Certificates of Analysis (CoA) by lot number.

References for IRAK4 Antibody, anti-human, REAfinity™


  1. Nahid, M. A. et al. (2013) Regulation of TLR2-mediated tolerance and cross-tolerance through IRAK4 modulation by miR-132 and miR-212. J Immunol 190(3): 1250-1263
  2. Li, S. et al. (2002) IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc. Natl. Acad. Sci. U.S.A. 99(8): 5567-5572
  3. Xiong, N. et al. (2012) CCR10 and its ligands in regulation of epithelial immunity and diseases. Protein Cell 3(8): 571-580

Related products for
IRAK4 Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?